Business
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n\n Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema\n LOS ANGELES, CA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced the first commercial sales of SofPulse™, its non-invasive, wearable Electroceutical™ device. SofPulse™ is the Company's FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.    \"We are very excited to begin sales of SofPulse™ under Endonovo management,\" said Endonovo CEO, Alan Collier. \"Our wearable Electroceutical™ was FDA-Cleared in 2008, but no significant effort to commercialize this revolutionary technology was ever undertaken. SofPulse™ has shown 80% acceleration in pain relief in breast augmentation patients and 2-fold less narcotics use in breast reconstruction patients.\" \"As we battle an opioid epidemic we must look for novel ways to relieve pain for people suffering from chronic pain, as well as preventing people undergoing surgical procedures from becoming dependent on narcotics. We believe our wearable Electroceutical™ can drastically reduce the need for pain medication use and improve the lives of millions of people suffering from pain.\" \"Unlike many of our competitors using electrical stimulation, some of whom have signed agreements with large device and pharmaceutical companies, our devices don't simply mask the pain, they address the underlying issue causing the pain, which is inflammation,\" stated Mr. Collier.   \"We are actively seeking to establish channel partnerships with global device and healthcare companies to commercialize our wearable Electroceuticals™ in Europe,\" concluded Mr. Collier. About SofPulse™ Electroceutical™ System SofPulse™ is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) t...